Intra-Cellular Therapies, Inc.
ITCIUnited States
39 filed reports · 320 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
| Figure | Latest fiscal year | Latest quarter |
|---|---|---|
| Revenue | $681MFY2024 · to Dec 31, 2024+46.6% from $464M10-K | $199MQ4 FY2024 · to Dec 31, 2024+50.8% from $132M10-K |
| Net income | -$74.7MFY2024 · to Dec 31, 2024a year earlier: -$140M10-K | -$16.9MQ4 FY2024 · to Dec 31, 2024a year earlier: -$28.6M10-K |
| Operating income | -$117MFY2024 · to Dec 31, 2024a year earlier: -$159M10-K | -$38.8MQ3 FY2024 · to Sep 30, 2024a year earlier: -$29.7M10-Q |
Filed reports
39 reports · Jun 2015 to Dec 2024Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 29 | 2,797 | Jun 2015 to Sep 2024 |
| Annual · 10-KSEC EDGAR | 10 | 3,140 | Dec 2015 to Dec 2024 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2024 | 10-K | Dec 31, 2024 | Feb 21, 2025 | 756 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Oct 30, 2024 | 178 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 7, 2024 | 142 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 7, 2024 | 144 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 22, 2024 | 321 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 2, 2023 | 114 | Open |
| FY2023 Q2 | 10-Q | Jun 30, 2023 | Aug 3, 2023 | 99 | Open |
| FY2023 Q1 | 10-Q | Mar 31, 2023 | May 4, 2023 | 103 | Open |
| FY2022 | 10-K | Dec 31, 2022 | Mar 1, 2023 | 288 | Open |
| FY2022 Q3 | 10-Q | Sep 30, 2022 | Nov 3, 2022 | 90 | Open |
| FY2022 Q2 | 10-Q | Jun 30, 2022 | Aug 9, 2022 | 86 | Open |
| FY2022 Q1 | 10-Q | Mar 31, 2022 | May 10, 2022 | 95 | Open |
Financial data
320 concepts · 5,937 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial311 concepts · 5,852 facts · Dec 2013 to Dec 2024
- Cash and cash equivalents at carrying value56 · Dec 2013 to Dec 2024
- Comprehensive income net of tax56 · Dec 2013 to Dec 2024
- Investment income interest56 · Dec 2013 to Dec 2024
- Net income loss56 · Dec 2013 to Dec 2024
- Operating income loss56 · Dec 2013 to Dec 2024
- Research and development expense56 · Dec 2013 to Dec 2024
- Share based compensation56 · Dec 2013 to Dec 2024
- Depreciation54 · Dec 2013 to Dec 2024
- General and administrative expense (US GAAP)54 · Dec 2013 to Sep 2024
- Increase decrease in accounts payable54 · Dec 2013 to Dec 2024
- Increase decrease in prepaid deferred expense and other assets54 · Dec 2013 to Dec 2024
- Proceeds from sale maturity and collections of investments54 · Dec 2013 to Dec 2024
- Proceeds from stock options exercised54 · Dec 2013 to Dec 2024
- Accretion amortization of discounts and premiums investments53 · Sep 2014 to Dec 2024
- Other comprehensive income availableforsale securities adjustment net of tax portion attributable to parent53 · Sep 2014 to Dec 2024
- Payments to acquire investments53 · Sep 2014 to Dec 2024
- Stockholders equity (US GAAP)53 · Dec 2013 to Dec 2024
- Common stock shares issued52 · Dec 2014 to Dec 2024
- Issuance of stock and warrants for services or claims52 · Dec 2014 to Dec 2024
- Payments to acquire property plant and equipment52 · Dec 2013 to Dec 2024
- Accounts payable current51 · Dec 2014 to Dec 2024
- Accrued employee benefits current51 · Dec 2014 to Dec 2024
- Accrued liabilities and other liabilities51 · Dec 2014 to Dec 2024
- Accumulated other comprehensive income loss net of tax51 · Dec 2014 to Dec 2024
Product2 concepts · 67 facts · Dec 2018 to Dec 2024
- Revenue52 · Dec 2019 to Dec 2024
- Advertising expense15 · Dec 2018 to Dec 2024
Segment7 concepts · 18 facts · Dec 2023 to Dec 2024
- Revenue6 · Dec 2023 to Dec 2024
- Cost Of Product Sales2 · Dec 2023 to Dec 2024
- Net income loss2 · Dec 2023 to Dec 2024
- Research and Development Expense, Other2 · Dec 2023 to Dec 2024
- Segment reporting other item amount2 · Dec 2023 to Dec 2024
- Selling, General and Administrative Expense, General and Administrative2 · Dec 2023 to Dec 2024
- Selling, General and Administrative Expense, Selling2 · Dec 2023 to Dec 2024
Segments
85 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service3 members · 67 facts
- Collaborative Arrangement, Product [Member]26 · Dec 2019 to Dec 2024
- Grant revenue [Member]26 · Dec 2019 to Dec 2024
- CAPLYTA [Member]15 · Dec 2018 to Dec 2024
Statement business segments1 member · 18 facts
- Reportable Segment18 · Dec 2023 to Dec 2024
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of Intra-Cellular Therapies, Inc. (ITCI) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.